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Abstract Grayscale IVUS and IVUS-based imag-
ing modalities during the last years have become
useful in the assessment not only of drug eluting
stent, but also of new bioresorbable vascular scaf-
folds. Although IVUS resolution is not sufficient for
determining stent coverage (optical coherence tomog-
raphy is the gold standard), serial IVUS can measure
intimal hyperplasia, assess acute and late incomplete
stent apposition, detect the presence and persistence
of edge dissections, study edge effects and look for
causes of restenosis and thrombosis. In addition other
IVUS-based imaging modalities, such as IVUS-VH,
iMAP or palpography, can be used to study the serial
compositional and mechanical changes of the plaque
behind stent struts and also to follow the bioresorp-
tion of the new bioresorbable scaffolds, analyzing the
backscattering signal coming from the polymeric
struts. This review details and evaluates grayscale
IVUS and IVUS-based techniques findings in clinical
trials, highlighting the usefulness of these imaging
modalities in the study of drug eluting stents and
bioresorbable vascular scaffold.
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Introduction
Intravascular ultrasound (IVUS) is an adjunctive
diagnostic technique that provides detailed cross-
sectional imaging of the coronary arteries. In addition
to assisting in the assessment of the morphology and
composition of coronary lesions and the appropriate
strategy to address them, IVUS can aid in confirming
the success of stent deployment and placement [1].
According to the 2005 American College of Cardi-
ology/American Heart Association/Society for Car-
diovascular Angiography and Interventions (ACC/
AHA/SCAI) 2005 Guideline Update for PCI, it is
reasonable to use IVUS to: (1) assess the adequacy of
coronary stent deployment, including the extent of
apposition and minimum luminal diameter within the
stent; (2) determine the cause of stent restenosis and
guide selection of appropriate therapy; (3) evaluate
coronary obstruction in a patient with a suspected
flow-limiting stenosis when angiography is difficult
because of location. These recommendations are
made based on a level of evidence that supports the
efficacy of IVUS. In addition, IVUS may be used to
assess lesion’s characteristics and vessel dimensions
before PCI to select an optimal revascularization
device, although the efficacy of this application is less
well established [2].
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Complementary to grayscale IVUS, tissue charac-
terization by IVUS radiofrequency data, among others,
Virtual Histology (VH) [3, 4] analysis has the potential
to add valuable information on the pathogenesis of
restenosis by providing information on plaque compo-
sition [5], on the change in composition of plaque behind
the stents [6] and on the quantification of bioresorption
process for new bioresorbable vascular scaffolds (BVS)
[7, 8]. At the same time iMAP and palpography are two
techniques that interpret the radiofrequency signal for
tissue characterization and for strain of the vessel wall.
All these techniques are relatively new and their clinical
usefulness has still to be elucidated.
This review focuses on the usefulness of IVUS
grayscale and IVUS-based imaging modalities in the
study of drug-eluting stents (DES) and bioresorbable
vascular scaffolds (BVS).
IVUS-guided des implantation
The use of IVUS imaging is associated with favorable
outcomes in patients who received DES implantation
during PCI [9–11]. A number of steps are recom-
mended to minimize the risk of adverse events.
Before stent deployment, IVUS should be used to
confirm that lesion severity warrants DES implanta-
tion. It is also important to identify proximal and
distal reference sites or ‘‘landing zones’’. To select a
DES size and length that will reduce the risk of a
proximal or distal edge stenosis, measure vessel size
and the distance between the proximal and distal stent
edge landing zones, respectively, in order to avoid the
longitudinal and axial geographical miss [12]. If
necessary, fine-tune the distance so that side branches
are not covered. Finally, select an anatomic structure
to serve as a fiduciary point linking IVUS imaging
and angiography. Post-intervention IVUS should be
used to identify and measure the minimum cross-
sectional area; under-expansion should be addressed
with additional inflations at higher pressure (compli-
ance charts of the manufacturers cannot be used to
guarantee adequate stent expansion). Proximal and
distal stent edges must be analyzed to reveal any
secondary uncovered plaques. The final step is to
ensure that important complications uncovered by
IVUS, such as lumen-compromising edge dissections,
intra- and extramural hematomas, and perforations,
are treated using appropriate clinical techniques.
Therefore, a number of technical issues are
associated with IVUS use in DES implantation,
including stent expansion, residual edge stenosis/
dissection, and malapposition.
IVUS assessment of DES expansion
Lesions that cause stent thrombosis after successful
DES deployment are often a consequence of stent
under-expansion and residual reference segment ste-
nosis, because inadequate expansion can lead to
abnormal shear stress (see Table 1, MUSIC criteria
of optimal stent expansion) [13]. For instance, Fujii
et al. [14], comparing all patients who received metallic
stent eluting sirolimus implantation and in which IVUS
was performed during PCI or at the time of stent
thrombosis, reported that the minimum stent cross-
sectional area (4.3 ± 1.6 mm2 vs. 6.2 ± 1.9 mm2,
P \ 0.001) and the degree of stent expansion (0.65 ±
0.18 vs. 0.85 ± 0.14, P \ 0.001) were significantly
smaller in the stent thrombosis group compared with
matched controls. A second study, which compared
IVUS imaging after DES implantation in 13 patients
with matched controls, reported similar findings [15].
DES patients who developed stent thrombosis showed
a smaller minimum stent area (4.6 ± 1.1 mm2 vs.
5.6 ± 1.7 mm2, P \ 0.0489) and a larger proximal
reference plaque burden (0.66 ± 0.08 vs. 0.56 ± 0.11,
Table 1 IVUS definitions
MUSIC criteria of optimal stent expansion:
1. Complete apposition of the stent over its entire length
against the vessel wall.
2. In-stent minimal lumen area C90% of the average
reference lumen area or C100% of lumen area of the
reference segment with the lowest lumen area. In-stent
lumen area of proximal stent entrance C90% of proximal
reference lumen area. In case the in-stent luminal area [90
mm2. In-stent minimal lumen area C 80% of the average
reference lumen area or C 90% of lumen area of the
reference segment with the lowest lumen area. In-stent
lumen area of proximal stent entrance C 90% of proximal
reference lumen area.
3. Symmetric stent expansion defined by stent diameter
min/stent diameter max C0.7.
Incomplete stent apposition (ISA): separation of at least 1
stent strut from the intimal wall not overlapping a side
branch with evidence of blood speckling (indicating flow):
Early if it is noted after stent implantation
Late-acquired if it was not present on IVUS analysis
baseline but developed during the follow-up period during
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P \ 0.0018). Thus, ensuring proper stent expansion is
essential for the prevention of DES stent thrombosis.
Inadequate stent expansion also increases the
likelihood of restenosis. Serial IVUS analysis from
the Sirolimus-Eluting Stent in Coronary Lesions
(SIRIUS) trial showed that a minimum stent area
\5.0 mm2 was responsible for the majority of SES
restenosis in the trial [16]. A study of IVUS
predictors of angiographic restenosis in a large series
of Korean patients (550 patients with 670 lesions)
treated with SES implantation found that the imme-
diate post-procedure IVUS cutoffs that best predicted
angiographic restenosis were a minimum stent cross-
sectional area of 5.5 mm2 and a stent length of
40 mm [17]. Finally, data from the TAXUS trials
identified 6.0 mm2 as the minimum stent area to
reduce the risk of revascularization. Examination of
sensitivity and specificity curves in these 3 analyses
confirmed that the minimum stent area that best
separated DES restenosis from no restenosis was
between 5.0 and 6.0 mm2, although it is not possible
to identify statistically a specific minimum stent cross
sectional area value, because in all studies there is a
stepwise relation between the final stent cross
sectional area and freedom from restenosis. Never-
theless, these studies showed that an optimal stent
expansion, especially in complex lesions, was asso-
ciated with an even lower rate of DES restenosis.
IVUS assessment of residual edge stenoses
or dissection
Residual plaque burden also is a predictor of late
stent thrombosis. In the retrospective study of metal-
lic stent eluting sirolimus implantation, Fujii et al.
reported also that the stent thrombosis group was
significantly more likely than control patients to have
residual edge stenosis (67% vs. 9%, P \ 0.001),
which was defined as edge lumen cross-sectional area
\ 4 mm2 and a plaque burden [70%. [14] Analysis
of IVUS parameters in SIRIUS trial patients estab-
lished a similar relation between longitudinal geo-
graphic miss and stent thrombosis. Sakurai et al.
examined 317 edges of 167 stents that had 18 edge
stenoses after 8 months [18]. Patients with peri-stent
stenosis had a significantly higher maximum refer-
ence plaque area compared to patients without peri-
stent stenosis (60.5% ± 9.0 vs. 48.8% ± 11.5,
P \ 0.030). These studies propose that longitudinal
geographic miss is associated with target lesions
revascularization.
It is noteworthy to consider also that the serial
geometrical changes at the edges of a stent vary
depending on the location (proximal vs. distal edge),
the shear stress conditions [19], the morphological
baseline characteristics of the segment (degree of
obstruction) and baseline tissue composition. In
TAXUS II [20], positive remodeling was observed
only at the distal edges in both the slow and moderate
release Taxus groups. This was almost entirely due to
an increase in plaque size and there was hardly any
change in lumen size. Meanwhile, in the TAXUS IV
study [21], almost no change was observed in vessel
size at the proximal edge and a trend towards
negative remodeling was observed at the distal edge.
It is difficult to put these two studies into perspective;
perhaps due to differences in sample size and
potential selection bias acknowledged by the authors
of TAXUS IV. In the ENDEAVOR II study [22],
IVUS analysis at 8 months found the minimum
luminal area in the distal edge of the metallic stent
eluting zotarolimus (ZES) to be significantly higher
than that of the bare metal stents (BMS). In detailed
sub-segmental analyses, loss of the mean luminal
area did not differ between the two stent groups at the
proximal edges. Conversely, at the first millimeter of
the distal edge, the mean plaque area increased more
with the BMS than the ZES, while the mean vessel
area was not different between the two groups. This
resulted in a significantly smaller mean luminal area
in the ZES than the BMS group.
IVUS evaluation of DES apposition
Incomplete stent apposition (ISA) (Table 1) has been
postulated to be one of the potential causes of stent
thrombosis after DES implantation. However, there
are no good data linking isolated acute stent malap-
position to adverse clinical events. The reported
prevalence of ISA post-stenting among DES studies
varies from 2.4 to 34.4% [21, 23–27]. On the other
hand, although late-acquired ISA has, by definition,
the same IVUS appearance as post-stenting ISA, its
postulated mechanisms are completely different
including progressive expansion of the vessel wall,
thrombus resolution and lack of tissue growth around
the stent struts [27]. In the literature, the incidence
ranges from 0.0 to 16.7% [17, 21, 23, 24, 26–29]. Of
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note, no clinical events related to ISA have been
reported in these trials. In other words, stent sizing
and residual disease are the critical parameters
associated with adverse outcomes.
Investigating the fate of incomplete stent apposition
in 168 consecutive patients with 182 lesions who
received SES, Kimura et al. found no clinical, proce-
dural, or IVUS measurement difference between
patients and lesions with isolated stent malapposition
and those without, although individuals with persistent
incomplete stent apposition were more likely to have
evidence of superficial lesion calcium [26]. Most cases
of acute stent malapposition resolved over time in this
study; those that did not, had no effect on the incidence
of stent thrombosis or in-stent restenosis. Similar
results were reported by Hong et al. who examined 557
patients with 705 native lesions who received DES
implantation with IVUS imaging [27]. Here, again,
late stent malapposition (at mean follow-up of
10.2 months) was not associated with any major
adverse cardiac events. More recently, Cook et al.
reported 11 patients with very late DES thromboses
and compared them with 198 controls that had
undergone routine IVUS follow-up but did not develop
stent thrombosis: incomplete stent apposition was
present at the time of thrombosis in 77% of patients
with very late DES thrombosis vs. 12% of controls
(P \ 0.0001) [30]. Very late DES thrombosis has been
also associated with histopathological and serological
signs of inflammation, in particular with eosinophil
infiltration: the ISA was associated with total eosino-
phil count [30].
IVUS and DES-restenosis
The MUSIC study [13] assessed the impact of IVUS-
guided stent implantation on the 6 months restenosis
rate. In this study, complete stent apposition, well
expansion (in-stent minimal lumen area[90% of the
average reference lumen area) and symmetric stent
expansion defined by minimum lumen diameter/
maximum lumen diameter C0.7 were considered for
assessing optimal stent deployment (Table 1). This
study demonstrated that satisfactory clinical and
angiographic outcome at 6 months can be achieved
by using IVUS guidance. It has already been
discussed above how an under-expansion of the stent
(minimum luminal cross sectional area between 5.0
and 6.0 mm2) may play an important role in stent
failure [16, 17]. Unfortunately, optimal minimum
stent area values are not frequently achieved in
current practice. In a study that enrolled 200 patients
with de novo coronary lesions treated with metallic
stents eluting either sirolimus (n = 133 patients) or
paclitaxel (n = 67 patients) under IVUS guidance,
24% of sirolimus-eluting stent and 28% of paclitaxel-
eluting stent did not achieve a final minimum stent
area of 5 mm2 [31].
Another reported cause of stent restenosis, poten-
tially valuable by IVUS, is stent fracture. At two US
centers 3,920 patients in a period of 1 year were
treated with drug-eluting stents, and in-stent resteno-
sis was reported in 188 patients (121 sirolimus-
eluting stent and 67 paclitaxel-eluting stent). In 35
patients out of 188 (18.6%) stent fracture was
observed. Only cases with severe stent fracture
(complete separation of stent segments) were
included and mild (single-strut fracture) and moder-
ate (more than one strut fracture, but without clear
separation of fractured stent segments) stent fractures
were excluded. In other words, it appears that in one-
fifth of the cases of in-stent restenosis, stent fracture
is the main mechanism of restenosis. The presence of
vessel tortuosity, use of SES and overlapping stents
were the factors more frequently associated with stent
fracture, while larger stent diameter was protective.
According to the authors of this study, high magni-
fication cine-angiography is the best method to
diagnose stent fracture and, although intravascular
ultrasound was performed in 10 out of the 35 cases of
stent fracture, it did not add any value to high
magnification cine-angiography [32]. However, in a
most recent article studying 83 lesions in 56 patients
by serial angiography and IVUS at baseline and at
6 months follow-up, Yamada et al. found that at
6 months by angiography no cases of stent fracture
were detected, while by IVUS 3 cases were detected
[33]. Moreover, IVUS is not only helpful to identify
stent fracture as cause of stent failure, but more
importantly to understand possible mechanisms of
stent fractures, such as aneurysm formation [34].
IVUS virtual histology
Regarding the vascular responses after stenting (i.e.
restenosis and remodeling), a response-to-injury
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pattern of wound healing occurs, mainly character-
ized by an increase in smooth muscle cells and
extracellular matrix [35]. This depends on the drug
type and the release kinetics. The most commonly
used DES, sirolimus- and paclitaxel eluting stents,
reduce restenosis by interfering with muscle cell
proliferation through different modes of action [36].
In this way, tissue characterization pre and post-
stenting with IVUS-VH is an important tool to define
plaque type pre-stent implantation and its temporal
modifications. VH (EagleEyeTM; Volcano Corpora-
tion, Rancho Cordova, CA, USA) uses an electronic
catheter that acquires ECG gated data for tissue
characterization. In addition, VH feeds the spectra
that are obtained from the radiofrequency data using
autoregressive models into a classification tree that
has reported diagnostic accuracies of over 90% for
each plaque component as compared to histology [4]
Four tissue components (necrotic core—red; dense
calcium—white; fibrous—green; and fibrofatty—
light green) were identified with this autoregressive
classification system [3, 37].
One of the proposed pathological mechanisms of
coronary stent thrombosis is stenting of necrotic core
rich plaques with extensive tissue prolapse and
plaque disruption in the proximity of the stented
arterial segment [38–40]. Thus, pre-stenting imaging
using IVUS-VH can give us an insight not only into
the extent of plaque, but also on the extent of necrotic
core within and beyond the intended stenting seg-
ment. In this context, studying 24 patients in whom
26 stented segments using IVUS-VH were assessed,
no stent thrombosis was observed, where necrotic
core rich areas were left unstented [40]. Ramcharitar
et al. presented a first clinical case of a patients with a
no culprit IVUS-VH derived thin capped fibroather-
oma, successful treated with PCI, with a good
6-month angiographic follow-up [41]. A large trial
in which patients are randomized to IVUS-VH or
angiography guided optimal coronary stenting is
required to draw firm conclusions.
Regarding stent evaluation by IVUS-VH, distinc-
tion should be made between metallic stents and
BVS. Kim et al. have previously shown that metallic
stents eluting sirolimus and paclitaxel introduce
artifacts in IVUS-VH images, that interfere with the
classification of plaque behind the struts [42]. Nor-
mally struts of drug-eluting stents appear as dense
calcium, surrounded by a red halo. Although the BVS
is made of non metallic materials, it was also
recognized by IVUS-VH software as dense calcium
and necrotic core. Moreover, for this scaffold, the
presence of ‘‘pseudo’’ dense calcium and necrotic
core could be used as quantitative surrogate for the
presence of the polymeric material of the BVS and
may help to evaluate the bioresorption process during
follow-up [7, 8, 43, 44]. Garcia-Garcia et al. have
already shown in a sub-study of ABSORB cohort A
trial that polymeric struts are identified with radio-
frequency backscattering signal as calcific structures
and that the ability of IVUS-VH to recognize
polymeric struts is important not only to study
imaging of the BVS post-implantation, but also to
potentially follow the mechanical support or biore-
sorption process [7] (Fig. 1).
Sarno et al. analyzing IVUS-VH plaque charac-
terization behind the first generation BVS found a
reduction in necrotic core component between
6-month and 2 year follow-up, probably related to a
synergistic effect of the bioresorption process and the
anti-inflammatory action of everolimus [8].
Since the stent’s struts are recognized by IVUS-
VH as dense calcium and necrotic core, however,
careful evaluation of exclusively the plaque behind
the stent should be done to avoid any misclassifi-
cation of the actual tissue [8, 42]. At the same time to
assess in-stent restenosis in metallic stents, IVUS-VH
has potential limitations in lack of validation of the
technique in this context.
Kubo et al., analyzing the long-term effects of
DES and of BMS on coronary arterial wall morphol-
ogy by IVUS-VH, have shown that DES-treated
lesions had a greater frequency of unstable lesion
morphometry at follow-up compared to BMS [6]. In
particular assessing the total amount of the four
color-VH components including also the contribution
of the stent, they found that DES-treated lesions
showed at follow-up a significantly higher incidence
of necrotic core abutting the lumen compared to
BMS-treated lesions, although there was not a
significant difference in necrotic core mean area
between the two groups. This was due to a suppres-
sion of the protective neointimal hyperplasia layer in
DES compared with BMS. Aoki et al. have demon-
strated in vivo that plaque volume behind the metallic
stent eluting sirolimus increases slightly at 4 months
follow-up and then significantly decreases at 4 years
follow-up compared to post-implantation and that
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change in echogenicity is suggestive of a change in
plaque composition [45]. He also documented a
significantly increase of plaque area outside metallic
stent eluting paclitaxel at 6 months, with its regres-
sion at 2 years [23]. In these situations, it would be
interesting to know what type of tissue contributed to
Fig. 1 Serial changes in
the struts of BVS 1.0 as
assessed by IVUS-VH. On
the left hand side, grayscale
IVUS images are shown at
pre-, post-implantation and
6-month follow-up. On the
right hand side, their
corresponding color code
VH images are depicted. Of
note, increased in dense
calcium (white) and
necrotic core (red) are noted
after BVS implantation. At
follow-up, a change in the
BVS’ strut appearance in
grayscale IVUS is noted
and decreases in the dense
calcium and necrotic core
contents in IVUS-VH
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this process and, from a quantitative point, to develop
a third (stent) contour in the VH software (VIAS or
pcVH) in order to characterize selectively intimal
hyperplasia and peri-stent tissue.
Edge effects assessed by IVUS-VH
Based on previous pathological studies, we hypoth-
esized that the tissue associated with increase of
plaque at the edges of the paclitaxel stent is mainly
fibro-fatty tissue as assessed by IVUS-VH. Fibro-
fatty, in IVUS-VH, has been described as loosely
packed bundles of collagen fibers with regions of
lipid deposition and extracellular matrix without
necrotic areas [39].
In the BETAX study [24, 46] patients (26 paclit-
axel eluting stents) were studied. Serial expansive
vascular remodeling was observed at the proximal
and distal edges of the stent to accommodate
fibrofatty and fibrous tissue growth. More specifi-
cally, proximal and distal segments were divided into
five sub-segments of 1-mm. In the first two sub-
segments adjacent to the proximal edge of the stent,
the vessel wall grew to compensate the plaque growth
without affecting the lumen size. In the following
three sub-segments, overcompensation (vessel wall
increased more than plaque size) was observed.
Consequently, the lumen size increased. At the distal
edge, overcompensation was observed in all five sub-
segments, followed by an increase in lumen size. In
summary, proximal and distal growth patterns were
characterized by an increase in fibrofatty tissue
(P \ 0.001 and P \ 0.001, respectively), decrease
in necrotic core (P = 0.014 and P \ 0.001, respec-
tively), and decrease in dense calcium content
(P \ 0.001 and P \ 0.001 respectively).
iMAP-IVUS
Unlike VH, iMapTM IVUS (iMap, 40 MHz, mechan-
ical-type transducer, 3.2 F Atlantis, Boston Scientific
Corporation) uses a 40 MHz single rotational trans-
ducer on a drive shaft and can acquire radiofrequency
data continuously. For the tissue characterization, it
uses a pattern recognition algorithm on the spectra
that were obtained from a fast fourier transformation
and a histology-derived database [47]. iMap has
higher resolution, but displays specific artifacts such
as non-uniform rotational distortion because it is a
rotational catheter.
Shin et al., compared in vivo iMap and VH for the
detection of coronary atherosclerotic plaques and
stent’s struts [48]. iMap showed all struts of a stent
separately where VH showed sometimes a continuum
in between struts. Moreover, VH tended to overes-
timate metallic stent struts, and iMap showed thinner
stent thickness than VH. Also, there was peri-stent
and calcium necrotic core halo in VH that was not
seen in iMap (Fig. 2). For these reasons, iMap may
be a good technique for metallic stent studies with
serial evaluation because it provides clearer images
of stent struts and does not produce necrotic tissue
around stent struts. The stent struts were misclassified
and overestimated as calcium in VH. VH also
increases the estimated amount of necrotic tissue in
stented lesion, which is shown as necrotic core
around the stent that is an artifact and should not be
interpreted as peri-strut inflammation or necrotic core
[42]. For these reasons, the study of overtime
modification of dense calcium and necrotic core
content of the plaque behind stent struts, especially
behind the polymeric struts of a BVS, could be more
accurate by iMAP.
Palpography
Palpography is an IVUS-based technique that
assesses the local mechanical properties of the
coronary plaque. The technique measures the relative
displacements of backscattered radiofrequency sig-
nals, recorded during IVUS acquisition, at two
different blood pressure levels to detect differences
in deformability or strain of various plaque compo-
nents. As such, lipid-rich plaques will deform more
and thus show a higher strain value compared with
calcified or fibrous plaques [49]. Palpography data
are acquired during a conventional IVUS pullback
with a commercially available catheter (20 MHz
Jovus Avanar, Volcano, Rancho Cordova, Califor-
nia). Plaque strain values are classified according to
the Rotterdam classification (ROC) score in a range
from I to IV (ROC I: 0–0.6%; ROC II: 0.6 to\0.9%;
ROC III: 0.9 to \1.2%; ROC IV: [1.2%) [50].
Palpography has been used to evaluate post-
implantation effect of BVS. In a sub-study of the
ABSORB A trial, the mean cumulative strain values
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in all frames with ROC I-IV scores changed from
0.50 ± 0.27–0.20 ± 0.10% (P = 0.0034) [7]. In
6 months follow-up the mean cumulative strain
values in all frames with ROC I-IV scores increased
significantly, compared to post-implantation. Deploy-
ment of a stent against the vessel wall undoubtedly
modifies the physical properties of the endoluminal
surface. With BVS, the reduction of the high strain
values immediately post-BVS implantation may be
due to a real decrease in deformability of the
scaffolded vessel wall. Alternatively, it may also
reflect an ultrasonic artifact, namely the incapability
of palpography to measure intrinsic changes in strain
of the vessel due to the acoustic properties of the
BVS struts preventing a proper propagation of
radiofrequency signal behind them. The following
increase of the strain values at follow-up may be an
indirect indicator of modification in strut structure of
BVS [7, 43, 44].
New frontiers: optical coherence tomography
With the increasing diffusion of the Optical Coher-
ence Tomography (OCT), it is important to consider
its differences with the ultrasound imaging modalities
in guided coronary intervention. OCT images provide
a clear depiction of the boundaries between lumen
and vessel. OCT’s ability to penetrate and delineate
calcium in the vessel wall makes it well suited to
guide complex interventional strategies in vessels
with superficial calcification [51]. OCT has also
higher sensitivity compared with IVUS for detection
of malapposed strut [52]. Plaque protrusion and stent-
edge dissection are other common intervention-
related parameters readily visible on OCT images,
although their clinical impact remains to be assessed.
Conclusions
IVUS is the most widely available tool for assessing
most features of stent implantation. Evaluation of
optimal stent deployment, good stent apposition and
coverage of the plaque are very important topics to
consider when a PCI with DES is performed and
IVUS is helpful to the operator. Probably IVUS
should be performed in all patients with DES failure
to better understand the pathophysiology. IVUS-VH
can add complementary information to study the edge
effects in metallic stents and can give insights into the
temporal compositional changes in bioresorbable
scaffold studies. iMAP probably is a better method
to obtain information about changes in bioresorbable
scaffold, due to less artifacts in stent struts mis-
reading; however, there are no data on this.
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